| 【英語タイトル】Global mRNA Synthesis Raw Material Market Size study & Forecast, by Product (Capping agents, nucleotides, plasmid DNA, others) by Application (Therapeutics Production, Vaccine Production, Others), by End-user (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutions) and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23MA090
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年4月1日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：バイオ
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社の本調査資料では、2021年に2,746百万ドルであった世界のmRNA合成原材料市場規模が、2022年〜2029年にかけて年平均2.1%で成長すると予測しています。本資料は、mRNA合成原材料の世界市場について市場実態を明らかにするとともに、今後の動向を展望したレポートです。エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、製品別（キャッピング剤、ヌクレオチド、プラスミドDNA、その他）分析、用途別（治療薬生産、ワクチン生産、その他）分析、エンドユーザー別（バイオ医薬品・製薬企業、CRO・CMO、学術・研究機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなどの項目で構成されています。また、主要参入企業として、Pfizer Inc.、Moderna, Inc.、BioNTech SE、Bayer AG、GlaxoSmithKline、Boehringer Ingelheim、CureVac、Sarepta Therapeutics、Alnylam Pharmaceuticals、Ionis Pharmaceuticalsなどの情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界のmRNA合成原材料市場規模：製品別
- キャッピング剤の市場規模
- ヌクレオチドの市場規模
- プラスミドDNAの市場規模
- その他製品の市場規模
・世界のmRNA合成原材料市場規模：用途別
- 治療薬生産における市場規模
- ワクチン生産における市場規模
- その他用途における市場規模
・世界のmRNA合成原材料市場規模：エンドユーザー別
- バイオ医薬品・製薬企業における市場規模
- CRO・CMOにおける市場規模
- 学術・研究機関における市場規模
・世界のmRNA合成原材料市場規模：地域別
- 北米のmRNA合成原材料市場規模
- ヨーロッパのmRNA合成原材料市場規模
- アジア太平洋のmRNA合成原材料市場規模
- 中南米のmRNA合成原材料市場規模
- その他地域のmRNA合成原材料市場規模
・競争分析
・調査プロセス |
Global mRNA synthesis raw material market is valued at approximately USD2746 million in 2021and and is anticipated to expand at a compound annual growth rate (CAGR) of 2.1% over the forecast period 2022-2029.Using a template consisting of the DNA nucleotide sequence, mRNA is created by the transcription process in the nucleus.mRNA’s adaptability and flexibility make it an excellent platform for developing therapeutic or preventive vaccines for a range of chronic and infectious diseases.The growing incidence of cancer and chronic disorders has raised the demand for gene treatments.
The market for mRNA synthesis and manufacturing services is expected to increase significantly over the next few years as a result of the rising demand for gene therapies, and the rise in chronic and infectious diseases. Funding is being provided for the creation of new mRNA therapies to numerous market participants and research institutions. For instance, the Canadian government provided USD 11.1 million in financing to the University of Columbia in October 2022 to further the development of mRNA vaccines. During the current Covid-2019 pandemic, many companies have chosen mRNA vaccine technology to combat coronavirus. Similarly, in December 2022, ExPLoRNA Therapeutics received USD 813,578 in funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. The emerging involvement of several market players is expected to drive the market further. The development of mRNA synthesis raw materials is hampered by a lack of adaptive, durable, and reasonably priced manufacturing procedures. The high cost of raw resources is the main impediment to progress.
The key regions considered for the Global mRNA synthesis raw material market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market for raw materials used in mRNA synthesis. The United States is forecasted to keep up its position as the industry leader because ofthe existence of sizable mRNA vaccine production facilities by renowned companies such asPfizer and Moderna. Due to this, this region will maintain its dominance throughout the forecast period. A significant percentage of the global market for mRNA synthesis raw materials was owned by Asia Pacific, which is anticipated to be the fastest-growing region due to rising R&D expenditures, a growth in the prevalence of infectious diseases, and a quick uptake of cutting-edge technology.
Major market player included in this report are:
Pfizer Inc.
Moderna, Inc.
BioNTech SE
Bayer AG
GlaxoSmithKline
Boehringer Ingelheim
CureVac
Sarepta Therapeutics
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Recent Developments in the Market:
In November 2022, The BASE and Sartorius formed an alliance to facilitate the sharing of development methodologies and strategies for various nucleic acid-based products. The collaboration will enable the efficient application of cutting-edge methods and analytical thinking to design and plan techniques for nucleic acid products.
Thermo Fisher Scientific unveiled a customised Dynabeads solution in October 2022, claiming that it aids in the synthesis and purification of mRNA for use in developing and manufacturing vaccines.
A final deal was signed by Sanofi in August 2021 to buy all of the outstanding shares of Translate Bio, a company that develops therapies for messenger RNA (mRNA). The purchase is a component of Sanofi’s goal to hasten the application of mRNA technology in the creation of pharmaceuticals and vaccines.
Global mRNA synthesis raw material marketReport Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, application, end-user, region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporatespotential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Capping Agents
Nucleotides
Plasmid DNA
Others
By Application:
Therapeutics Production
Vaccine Production
Others
By End-user:
Biopharmaceutical & Pharmaceutical Companies CROs & CMOs
Academic & Research Institutions
By Region:
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. mRNA Synthesis Raw Material Market, by Region, 2019-2029 (USD Million)
1.2.2. mRNA Synthesis Raw Material Market, by Type,2019-2029 (USD Million)
1.2.3. mRNA synthesis raw material Market, by Application, 2019-2029 (USD Million)
1.2.4. mRNA synthesis raw material Market, by End-user, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global mRNA Synthesis Raw Material Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global mRNA Synthesis Raw Material Market Dynamics
3.1. mRNA Synthesis Raw Material Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing incidence of cancer and chronic disorders
3.1.1.2. Active Involvement of big pharma players
3.1.2. Market Challenges
3.1.2.1. High Cost of mRNA Synthesis Raw Material
3.1.3. Market Opportunities
3.1.3.1. Necessity created by COVID-19
3.1.3.2. Considerable benefits of mRNA
Chapter 4. Global mRNA Synthesis Raw Material Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global mRNA Synthesis Raw Material Market, by Type
6.1. Market Snapshot
6.2. Global mRNA Synthesis Raw Material Market by Type, Performance – Potential Analysis
6.3. Global mRNA Synthesis Raw Material Market Estimates & Forecasts by Type 2019-2029 (USD Million)
6.4. mRNA Synthesis Raw Material Market, Sub Segment Analysis
6.4.1. Capping Agents
6.4.2. Nucleotides
6.4.3. Plasmid DNA
6.4.4. Others
Chapter 7. Global mRNA synthesis raw material Market, by Application
7.1. Market Snapshot
7.2. Global mRNA synthesis raw material Market by Application, Performance – Potential Analysis
7.3. Global mRNA synthesis raw material Market Estimates & Forecasts by Application2019-2029 (USD Million)
7.4. mRNA synthesis raw material Market, Sub Segment Analysis
7.4.1. Therapeutics Production
7.4.2. Vaccine Production
7.4.3. Others
Chapter 8. Global mRNA synthesis raw material Market, by End-user
8.1. Market Snapshot
8.2. Global mRNA Synthesis Raw Material Market by End-user, Performance – Potential Analysis
8.3. Global mRNA synthesis raw material Market Estimates & Forecasts by End-user 2019-2029 (USD Million)
8.4. mRNA synthesis raw material Market, Sub Segment Analysis
8.4.1. Biopharmaceutical & Pharmaceutical Companies
8.4.2. CROs & CMOs
8.4.3. Academic & Research Institution
Chapter 9. Global mRNA Synthesis Raw Material Market, Regional Analysis
9.1. mRNA Synthesis Raw Material Market, Regional Market Snapshot
9.2. North America mRNA Synthesis Raw Material Market
9.2.1. U.S.mRNA Synthesis Raw Material Market
9.2.1.1. Type breakdown estimates & forecasts, 2019-2029
9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
9.2.1.3. End-user breakdown estimates & forecasts, 2019-2029
9.2.2. Canada mRNA Synthesis Raw Material Market
9.3. Europe mRNA Synthesis Raw Material Market Snapshot
9.3.1. U.K. mRNA Synthesis Raw Material Market
9.3.2. Germany mRNA Synthesis Raw Material Market
9.3.3. France mRNA Synthesis Raw Material Market
9.3.4. Spain mRNA Synthesis Raw Material Market
9.3.5. Italy mRNA Synthesis Raw Material Market
9.3.6. Rest of Europe mRNA Synthesis Raw Material Market
9.4. Asia-Pacific mRNA Synthesis Raw Material Market Snapshot
9.4.1. China mRNA Synthesis Raw Material Market
9.4.2. India mRNA Synthesis Raw Material Market
9.4.3. Japan mRNA Synthesis Raw Material Market
9.4.4. Australia mRNA Synthesis Raw Material Market
9.4.5. South Korea mRNA Synthesis Raw Material Market
9.4.6. Rest of Asia Pacific mRNA Synthesis Raw Material Market
9.5. Latin America mRNA Synthesis Raw Material Market Snapshot
9.5.1. Brazil mRNA Synthesis Raw Material Market
9.5.2. Mexico mRNA Synthesis Raw Material Market
9.6. Rest of The World mRNA Synthesis Raw Material Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Pfizer Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Type Summary
10.2.1.5. Recent Developments
10.2.2. Moderna, Inc.
10.2.3. BioNTech SE
10.2.4. Bayer AG
10.2.5. GlaxoSmithKline
10.2.6. Boehringer Ingelheim
10.2.7. CureVac
10.2.8. Sarepta Therapeutics
10.2.9. Alnylam Pharmaceuticals
10.2.10. Ionis Pharmaceuticals
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
